Need more information in your inbox? Digging for more data? A premium subscription provides both full text email alerts and access to archived news.
Support Biomarker Commons There are currently 14 users online Biomarker Commons JobsLatest Biomarker NewsSearch Biomarker NewsBiomarker News Email AlertsReach your targeted audience: advertise with us
|
Huntington's diseaseRoche and Isis Pharmaceuticals Form Alliance for Huntington's DiseaseRoche (SIX: RO, ROG; OTCQX: RHHBY) and Isis Pharmaceuticals, Inc (NASDAQ: ISIS) recently announced that they have formed an alliance to develop treatments for Huntington's disease (HD) based on Isis' antisense oligonucleotide (ASO) technology. This alliance combines Isis' antisense expertise with Roche's scientific expertise in developing neurodegenerative therapeutics. In addition, Isis and Roche will be collaborating to combine Isis' ASOs and Roche's proprietary "brain shuttle" program with the objective of increasing the brain penetration of ASOs with systemic administration.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
Premium Subscription Required for AccessArchived news access requires a Premium Subscription. A Premium Subscription allows you and your organization full-text access to aggregated news dating back to April 2010. Need quick access? A 30-day Premium Subscription costs $49.95. Looking for a longer access option? Our annual premium subscription costs $99.95. In addition to full-text access, an Annual Premium Subscription provides an additional benefit: you'll receive the latest Biomarker Commons news stories via email in full text instead of our standard partial/excerpt text alerts. Questions? Use the contact form.
Tags:
|
